Bindley Capital Amends Guardian Pharmacy Stake on March 24, 2026

TL;DR

**Bindley Capital just updated its ownership in Guardian Pharmacy, watch for potential moves!**

AI Summary

Bindley Capital Partners I, LLC filed a Schedule 13D/A on March 24, 2026, indicating an amendment to their beneficial ownership in Guardian Pharmacy Services, Inc. This filing updates previous disclosures about Bindley Capital's stake in Guardian Pharmacy, a company operating in the retail drug stores sector. This matters to investors because Schedule 13D filings signal significant ownership stakes and potential influence over a company's direction, which can impact stock performance.

Why It Matters

This filing updates the public record on a significant investor's stake, which can signal potential strategic moves or changes in influence over Guardian Pharmacy Services, Inc.

Risk Assessment

Risk Level: low — This is an informational filing updating ownership, not indicating an immediate financial risk or opportunity.

Analyst Insight

Investors should note the updated ownership stake by Bindley Capital Partners I, LLC in Guardian Pharmacy Services, Inc. and monitor future filings for any further changes or indications of activist intent, as significant ownership can precede strategic shifts.

Key Players & Entities

• Bindley Capital Partners I, LLC (company) — entity filing the Schedule 13D/A
• Guardian Pharmacy Services, Inc. (company) — the subject company in which ownership is being reported
• March 24, 2026 (date) — filing date of the Schedule 13D/A
• 0002038820 (person) — CIK for Bindley Capital Partners I, LLC
• 0001802255 (person) — CIK for Guardian Pharmacy Services, Inc.

FAQ

Key Financial Figures

• $0.001 — ssuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities

Filing Documents

• primary_doc.html (SCHEDULE 13D/A)
• primary_doc.xml (SCHEDULE 13D/A) — 33KB
• ck0000000000-ex24_1.pdf (EX-24.1) — 82KB
• 0001193125-26-122330.txt ( ) — 148KB

Security and Issuer

Item 1. Security and Issuer (a) Title of Class of Securities: Class A Common Stock, par value $0.001 per share (b) Name of Issuer: Guardian Pharmacy Services, Inc. (c) Address of Issuer's Principal Executive Offices: 300 Galleria Parkway SE, Suite 800, Atlanta, GEORGIA , 30339.

Comment

Item 1 Comment: EXPLANATORY NOTE: This Schedule 13D is intended to serve as Amendment No. 3 to the Statement on Schedule 13D ("Amendment No. 3") related to the shares of Class A common stock, par value $0.001 per share ("Class A common stock") of Guardian Pharmacy Services, Inc. (the "Issuer"), and amends the initial statement on Schedule 13D filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, Amendment No. 2 thereto filed on July 29, 2025, and as further amended by this Amendment No. 3 (collectively, "Schedule 13D"). Except as specifically provided herein, this Amendment No. 3 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 3 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 3 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons").

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration   As of the date hereof, the Reporting Persons, collectively, beneficially own 17,929,985 shares of class A common stock.

Purpose of Transaction

Item 4. Purpose of Transaction

of the Schedule 13D is amended and supplemented as follows

Item 4 of the Schedule 13D is amended and supplemented as follows: On March 20, 2026, the Reporting Persons sold an aggregate amount of 5,880,000 shares of Class A common stock of the Issuer pursuant to an underwriting agreement, dated as of March 18, 2026, by and among the Issuer, the selling stockholders party thereto, and BofA Securities, Inc. and Jefferies LLC, as representatives of the several underwriters (the "Underwriters") named therein (the "Underwriting Agreement"). Pursuant to the Underwriting Agreement, on March 20, 2026, the Underwriters exercised in full their option to purchase an additional 900,000 shares of Class A common stock from the Reporting Persons.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a) As of the date hereof, the Reporting Persons, collectively, beneficially own 17,929,985 shares of Class A common stock, representing approximately 36.0% of the shares of Class A common stock. The percentage calculated based on 49,781,181 shares of Class A common stock, which consists of (i) 36,259,762 shares of Class A common stock outstanding the Issuer as of March 13, 2026, as disclosed in the Prospectus, and (ii) 13,521,419 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on March 28, 2026. (b) The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference. (c) Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D. (d) Except as described herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A common stock of the Issuer beneficially owned by the Reporting Persons as described in this Item 5. (e) Not applicable.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer   In connection with the Underwriting Agreement, the Reporting Persons entered into lock-up agreements with the Underwriters pursuant to which they agreed, for a period of 180 days after the date of the Underwriting Agreement, not to directly or indirectly offer, sell, contract to sell or otherwise dispose of or transfer any shares of the Issuer's common stock or any securities convertible into or exchangeable for shares of the Issuer's common stock, without the prior written consent of BofA Securities, Inc. and Jefferies LLC. These agreements also preclude any hedging, collar or other transaction designed or reasonably expected to result in a disposition of shares of the Issuer's common stock or securities convertible into or exercisable or exchangeable for shares of the Issuer's common stock. BofA Securities, Inc. and Jefferies LLC may, in its sole discretion and at any time, release all or any portion of the securities subject to these agreements.

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits.   Exhibit 24.1 Power of Attorney Exhibit 99.1 Stockholders' Agreement, dated as of September 25, 2024, by and among Guardian Pharmacy Services, Inc., Bindley Capital Partners I, LLC, Pharmacy Investors, LLC, Cardinal Equity Fund LP, Fred Burke, David Morris and Kendall Forbes (incorporated by reference to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2024). Exhibit 99.2 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated by reference to the Initial Schedule 13D filed with the Securities and Exchange Commission on February 3, 2025).     SIGNATURE     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.   Bindley Capital Partners I, LLC   Signature: /s/ Thomas J. Salentine, Jr. Name/Title: Member Date: 03/24/2026   William E. Bindley   Signature: /s/ William E. Bindley, individually Name/Title: William E. Bindley, individually Date: 03/24/2026   Thomas J. Salentine, Jr.   Signature: /s/ Thomas J. Salentine, Jr., individually Name/Title: Thomas J. Salentine, Jr., individually Date: 03/24/2026   Pharmacy Investors, LLC   Signature: /s/ John Ackerman Name/Title: Managing Member Date: 03/24/2026   John Ackerman   Signature: /s/ John Ackerman, individually Name/Title: John Ackerman, individually Date: 03/24/2026   Cardinal Equity Fund, L.P.   Signature: /s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner Name/Title: Managing Member Date: 03/24/2026   Fred P. Burke   Signature: /s/ Fred P. Burke, individually Name/Title: Fred P. Burk

View Full Filing

View this filing on SEC EDGAR